Novo Nordisk Eyes Social Inequality To Enhance Access To Wegovy: 'Have To Be More Intentional'
Portfolio Pulse from Benzinga Neuro
Novo Nordisk's CEO, Lars Fruergaard Jorgensen, announced plans to collaborate with European healthcare systems to improve access to its weight-loss drug, Wegovy, for less fortunate and more obese individuals. The company aims to seek reimbursement for patients with the highest BMI and those less fortunate from a socio-economic point of view. Wegovy leads to an average weight loss of around 15% when used alongside dietary and exercise changes.
August 25, 2023 | 11:24 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Novo Nordisk's plans to improve access to its weight-loss drug, Wegovy, could potentially increase its market reach and customer base.
Novo Nordisk's initiative to collaborate with European healthcare systems to improve access to its weight-loss drug, Wegovy, for less fortunate and more obese individuals could potentially increase its market reach and customer base. This could lead to increased sales and revenue for the company, positively impacting its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100